Showing results (101-110 of 146) with videos related to
Sort By:
Pageof 15
Journal of Gynecologic Oncology|April 17, 2026
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort resultsYoung Kwang Chae, Josie Czeskleba, Sandip Pravin Patel, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033Charles D Blanke, Cathryn Rankin, George D Demetri, et al.Urology|February 11, 2023
Fumarate Hydratase Variants and Their Association With Paraganglioma/PheochromocytomaShirin Zavoshi, Eric Lu, Paul C Boutros, et al.JAMA Oncology|February 15, 2017
Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033Michael C Heinrich, Cathryn Rankin, Charles D Blanke, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2024
Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810Leonard J Appleman, Se Eun Kim, Wayne B Harris, et al.Cancer|November 12, 2024
A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinibJayesh Desai, Andrew J Wagner, Irene Carrasco Garcia, et al.Journal of the National Comprehensive Cancer Network : JNCCN|August 13, 2018
DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate CancerEric Lu, George V Thomas, Yiyi Chen, et al.Journal of Clinical Medicine|January 11, 2025
Predictive Value of FDG Uptake on PET for Future Immune Checkpoint Inhibitor-Mediated Colitis: A Case SeriesMalek Shatila, Kei Takigawa, Yang Lu, et al.Cancer|November 1, 2021
Fumarate hydratase variant prevalence and manifestations among individuals receiving germline testingEric Lu, Kathryn E Hatchell, Sarah M Nielsen, et al.The Lancet. Oncology|January 23, 2016
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trialAndrew J Armstrong, Susan Halabi, Tim Eisen, et al.Pageof 15